Pfizer Inc. (NYSE:PFE) Shares Sold by Compass Wealth Management LLC

Compass Wealth Management LLC cut its stake in Pfizer Inc. (NYSE:PFE) by 47.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,956 shares of the biopharmaceutical company’s stock after selling 4,522 shares during the period. Compass Wealth Management LLC’s holdings in Pfizer were worth $131,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in PFE. Monte Financial Group LLC lifted its position in shares of Pfizer by 6.6% during the fourth quarter. Monte Financial Group LLC now owns 208,327 shares of the biopharmaceutical company’s stock worth $5,527,000 after purchasing an additional 12,883 shares during the last quarter. Gradient Investments LLC lifted its holdings in Pfizer by 19.8% during the 4th quarter. Gradient Investments LLC now owns 1,109,832 shares of the biopharmaceutical company’s stock worth $29,444,000 after buying an additional 183,403 shares during the last quarter. Curated Wealth Partners LLC grew its position in shares of Pfizer by 25.6% in the 4th quarter. Curated Wealth Partners LLC now owns 45,337 shares of the biopharmaceutical company’s stock worth $1,203,000 after acquiring an additional 9,236 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of Pfizer by 10.2% in the 4th quarter. Exchange Traded Concepts LLC now owns 76,250 shares of the biopharmaceutical company’s stock valued at $2,023,000 after acquiring an additional 7,072 shares during the last quarter. Finally, CX Institutional increased its holdings in shares of Pfizer by 9.1% in the 4th quarter. CX Institutional now owns 50,390 shares of the biopharmaceutical company’s stock valued at $1,337,000 after acquiring an additional 4,183 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on PFE. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. Truist Financial lowered their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Wolfe Research began coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price for the company. Finally, Citigroup started coverage on Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Pfizer Stock Down 1.3 %

Pfizer stock opened at $26.10 on Friday. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The stock has a market cap of $147.89 billion, a price-to-earnings ratio of 35.27, a PEG ratio of 0.64 and a beta of 0.64. The company’s 50-day moving average price is $26.11 and its two-hundred day moving average price is $27.94. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same period last year, the firm earned ($0.17) EPS. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. On average, analysts expect that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.59%. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 11.11 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.